Health Care & Life Sciences » Biotechnology | Panacos Pharmaceuticals Inc.

Panacos Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2003
2004
2005
2006
2007
Sales/Revenue
1,077.90
1,336.90
1,049.00
284.00
180.00
Cost of Goods Sold (COGS) incl. D&A
-
112.00
628.00
-
-
Gross Income
-
1,224.90
421.00
-
-
SG&A Expense
5,408.90
13,193.90
27,215.00
41,228.00
37,392.00
Unusual Expense
-
-
33,190.00
-
1,272.00
Non Operating Income/Expense
-
-
6.00
6.00
15.00
Interest Expense
185.60
143.10
-
-
1,127.00
Pretax Income
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
Consolidated Net Income
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
Net Income
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
Net Income After Extraordinaries
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
Net Income Available to Common
4,508.00
12,038.30
59,078.00
38,110.00
37,459.00
EPS (Basic)
-
3.00
1.72
0.75
0.70
Basic Shares Outstanding
-
3,950.70
34,423.00
50,523.00
53,145.00
EPS (Diluted)
-
3.05
1.72
0.75
0.70
Diluted Shares Outstanding
-
3,950.70
34,423.00
50,523.00
53,145.00
EBITDA
4,252.60
11,857.10
26,166.00
40,944.00
37,212.00
Non-Operating Interest Income
8.60
73.80
912.00
3,591.00
2,705.00

About Panacos Pharmaceuticals

View Profile
Address
134 Coolidge Avenue
Watertown Massachusetts 02472
United States
Employees -
Website http://www.panacos.com
Updated 07/08/2019
Panacos Pharmaceuticals, Inc. is a development stage company engaged in the discovery and development of small-molecule oral drug which is designed to treat Human Immunodeficiency Virus and other major human viral diseases. Its primary product is Bevirimat which is an oral human immunodeficiency virus which provides a novel mechanism of action called maturation inhibition. The company was founded by Graham Allaway in March 2005 and is headquartered in Watertown, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.